Can a patient on pembrolizumab (Keytruda) combined with carboplatin and docetaxel safely receive the shingles vaccine and the pneumococcal vaccine, and undergo a colonoscopy during treatment?

Vaccination and Colonoscopy During Pembrolizumab, Carboplatin, and Docetaxel Treatment

Yes, patients on pembrolizumab (Keytruda) with carboplatin and docetaxel can and should receive both the recombinant zoster vaccine (Shingrix) and pneumococcal vaccine during treatment, and can safely undergo colonoscopy with appropriate precautions.

Vaccination Recommendations

Recombinant Zoster Vaccine (Shingrix)

The recombinant zoster vaccine is specifically recommended for patients ≥18 years who are at increased risk for herpes zoster, including those receiving immunosuppressive cancer therapy 1. This is a non-live, adjuvanted vaccine that has been studied in patients with solid tumors and shown to be immunogenic even during active treatment 2.

Key points:

• Two doses given 2-6 months apart (or 1-2 months apart for those needing a shorter schedule) 1
• Can be administered during chemotherapy, though humoral responses tend to be higher when given before or after immunosuppressive therapy rather than during 2
• Grade 3 local adverse events (injection-site pain) occur in 12-13% of patients, and Grade 3 general adverse events in 16-22% 2
• The risk of herpes zoster is particularly elevated in the first 2 years following cancer diagnosis, making vaccination critical 2

Pneumococcal Vaccine

Newly diagnosed cancer patients who are pneumococcal vaccine-naïve should receive PCV20 (preferred single dose) or PCV15 followed by PPSV23 at least 8 weeks later 1.

• Patients with cancer face significantly higher risk of invasive pneumococcal disease compared to the general population 2
• The vaccine can be given on the day of chemotherapy or 2 weeks before initiation with comparable immune responses 2

Important Vaccination Caveats

• Live vaccines are absolutely contraindicated during chemotherapy 1
• All household members should be up-to-date with vaccines 1
• Immune responses may be lower during active immunosuppressive therapy, but vaccination is still recommended as the benefits outweigh risks 2

Colonoscopy During Treatment

Colonoscopy can be performed during pembrolizumab, carboplatin, and docetaxel treatment, but requires careful consideration of timing and monitoring for immune-related adverse events.

Safety Considerations

The primary concern is immune-mediated colitis, which is a known adverse event with pembrolizumab:

• Pembrolizumab has a relatively lower incidence of colitis compared to other immune checkpoint inhibitors 3
• However, immune-mediated colitis can occur and typically develops 6-8 weeks after ICI initiation 4
• The Keytruda label reports diarrhea and colitis as recognized adverse reactions 5

Timing Recommendations

Schedule the colonoscopy when:

• The patient has adequate platelet counts (>50,000/μL ideally) given carboplatin and docetaxel myelosuppression
• Neutrophil count is adequate (ANC >1,000/μL) to minimize infection risk from bowel preparation and procedure
• The patient is not experiencing active diarrhea or GI symptoms that could indicate immune-mediated colitis

Critical Monitoring

Before and after colonoscopy:

• Exclude infectious causes if any diarrhea is present (stool studies for enteric pathogens, C. difficile) 4
• Monitor for signs of immune-mediated colitis: increased stool frequency, abdominal pain, blood in stool 4
• If colitis is suspected, grade severity and manage according to established protocols (corticosteroids for grade ≥2) 4

Procedural Precautions

• Ensure adequate bowel preparation is tolerated given potential for chemotherapy-related nausea
• Consider prophylactic antiemetics during bowel preparation
• Monitor for bleeding complications given thrombocytopenia risk from chemotherapy
• Communicate with the endoscopist about the patient's immunotherapy status

Common Pitfalls to Avoid

1. Do not delay vaccination waiting for "optimal" timing—the protection benefit during active treatment outweighs suboptimal immune response
2. Do not confuse recombinant zoster vaccine with the old live-attenuated vaccine—Shingrix is safe during chemotherapy; Zostavax was not
3. Do not assume all diarrhea is chemotherapy-related—always consider immune-mediated colitis in patients on pembrolizumab, especially if symptoms develop weeks after starting treatment
4. Do not proceed with colonoscopy if the patient has active, unexplained diarrhea—this could represent immune-mediated colitis requiring treatment before instrumentation